Quantification of biochemical PSA dynamics after radioligand therapy with [¹⁷⁷Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model.

ABSTRACT:

Background

There is an unmet need for prediction of treatment outcome or patient selection for [¹⁷⁷Lu]Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Quantification of the tumor exposure-response relationship is pivotal for further treatment optimization. Therefore, a population pharmacokinetic (PK) model was developed for [¹⁷⁷Lu]Lu-PSMA-I&T using SPECT/CT data and, subsequently, related to prostate-specific antigen (PSA) dynamics after therapy in patients with mCRPC using a pharmacokinetic/pharmacodynamic (PKPD) modelling approach.

Methods

A population PK model was developed using quantitative SPECT/CT data (406 scans) of 76 patients who received multiple cycles [¹⁷⁷Lu]Lu-PSMA-I&T (± 7.4 GBq with eit

SUBMITTER: Siebinga H 

PROVIDER: S-EPMC11043318 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature